One Biosciences, backed by Institut Curie, selected Albany, New York, for its first U.S. location to build a high-complexity lab and computational analytics operation. The company plans to use AI-driven single-cell technologies to characterize the tumor ecosystem for pharma, biotech, and academic collaborators. Empire State Development will support the expansion with up to $525,000 in performance-based Excelsior Jobs Program tax credits tied to job and investment commitments. One Biosciences said the Albany hub will accelerate adoption of its proprietary approach for clinical and scientific use, including services to map tumor heterogeneity and microenvironment features. The move underscores continued U.S. localization of platform-heavy biotech businesses that rely on integrated wet-lab and analytics capabilities.